LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer

Sheng-Jia Shi; Li-Juan Wang; Bo Yu; Yun-Hui Li; Yong Jin; Xiao-Zhong Bai

doi:10.18632/oncotarget.3457

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer

Sheng-Jia Shi, Li-Juan Wang, Bo Yu, Yun-Hui Li, Yong Jin and Xiao-Zhong Bai _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:11652-11663. https://doi.org/10.18632/oncotarget.3457

Metrics: PDF 4859 views | HTML 5466 views | ?

Abstract

Sheng-Jia Shi1,*, Li-Juan Wang2,*, Bo Yu1, Yun-Hui Li1, Yong Jin1, Xiao-Zhong Bai1

1Department of Administration and Department of Aristogenesis, No. 202 Hospital of PLA, No. 5, Shenyang, 110003, Liaoning Province, P.R. China

2Department of Oncology, the First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi’an, 710061, Shaanxi Province, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Xiao-Zhong Bai, e-mail: [email protected]

Keywords: lnc-ATB, trastuzumab resistance, EMT, TGF-β, breast cancer

Received: February 05, 2015 Accepted: February 25, 2015 Published: March 23, 2015

ABSTRACT

Trastuzumab resistance is leading cause of mortality in HER2-positive breast cancers, and the role of TGF-β-induced epithelial-mesenchymal transition (EMT) in trastuzumab resistance is well established, but the involvement of lncRNAs in trastuzumab resistance is still unknown. Here, we generated trastuzumab-resistant breast cancer cells with increased invasiveness compared with parental cells, and observed robust epithelial–mesenchymal transition (EMT) and consistently elevated TGF-β signaling in these cells. We identified long noncoding RNA activated by TGF-β (lnc-ATB) was the most remarkably upregulated lncRNA in TR SKBR-3 cells and the tissues of TR breast cancer patients. We found that lnc-ATB could promote trastuzumab resistance and invasion-metastasis cascade in breast cancer by competitively biding miR-200c, up-regulating ZEB1 and ZNF-217, and then inducing EMT. In addition, we also found that the high level of lnc-ATB was correlated with trastuzumab resistance of breast cancer patients. Thus, these findings suggest that lncRNA-ATB, a mediator of TGF-β signaling, could predispose breast cancer patients to EMT and trastuzumab resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3457

Publication Alerts

Research Papers:

LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer

Abstract